Anemia and Iron Deficiency in Heart Failure — Clinical Update

András Mester, Adriana Mitre, Erzsébet Lázár, István Benedek Jr, Johanna Kéri, Annamária Pakucs, István Benedek

University of Medicine and Pharmacy, Târgu Mureș, Romania

ABSTRACT

Iron deficiency and anemia affect approximately half of the chronic heart failure patients and they are associated with increased hospitalization rate, lower functional capacity, lower quality of life, and higher mortality. The exact mechanism of iron deficiency in heart failure patients is still not fully understood. Current guidelines recommend ferritin as the most accurate serum biomarker for the diagnosis of iron deficiency. The use of erythropoiesis-stimulating agents is no longer recommended because of the lack of improvement on mortality or hospital readmission rate, and it was associated with a higher rate of thromboembolic events. Intravenous iron replacement therapy is safe and generally well tolerated, with fewer side effects compared to oral administration. Large randomized studies with ferric carboxymaltose demonstrated its effectiveness and superiority to oral administration, and it was associated with a decreased rate of hospitalization rate and worsening heart failure, and improvement of functional capacity and quality of life. Intravenous iron supplementation for chronic heart failure is strongly recommended by European guidelines. Further studies are needed for a better knowledge of this complex pathology and determination of the long-term safety and effectiveness of iron administration in chronic heart failure patients.

Keywords: iron deficiency, anemia, heart failure

INTRODUCTION

Iron deficiency is one of the most frequent nutritional deficits around the world, particularly in developing countries, affecting mostly infants, children, pregnant women, elderly persons, and individuals with chronic conditions such as chronic kidney disease, inflammatory bowel disease, rheumatic and cardiovascular diseases. As an indispensable micronutrient, iron plays and important role in erythropoiesis and protein synthesis, but it is also essential in oxygen storage and transportation and many metabolic processes. These facts make it indispensable for the proper functioning of the nervous system, thyroid gland, musculoskeletal and cardiovascular system. Research carried out in the last decade observed a positive correlation between iron deficiency, anemia, and heart failure. Iron deficiency is observed in approximately half of the heart failure
patients, which further aggravates the quality of life and mortality of these patients. The underlying mechanism is still unknown, but animal models offer a possible answer in form of a link to chronic inflammation in these patients, which leads to absorption deficits. The first studies that published results regarding iron and erythropoietin administration to treat anemia in heart failure patients concluded that it improved the clinical status (New York Heart Association – NYHA functional class), echocardiographic parameters (left ventricular ejection fraction), and hemoglobin levels of the patients. Further study results confirmed this theory and proved the efficiency of iron administration for heart failure patients irrespective of anemia.

The aim of this clinical update is to summarize the current knowledge and clinical practice in the management of iron deficiency and anemia in heart failure patients.

**IRON METABOLISM**

The human body contains approximately 3–5 grams of iron, which is present in bivalent ferrous and trivalent ferric forms bound to proteins (approximately 75% to hemoglobin), but it is also present in other organs such as the musculoskeletal system. It is absorbed via dietary intake at the level of the duodenum and jejunum, and it is mainly stored as ferritin (500–1000 mg) in the hepatocytes, spleen and bone marrow, which should cover the iron demand of up to 36 months in men and 6 months in women due to the regular menstrual cycle. The iron metabolism is modulated by the liver-derived hepcidin, which inhibits the release of iron from the enterocytes by blocking of ferroportin receptor. Inflammatory cytokines stimulate hepcidin synthesis resulting in the blockage of iron supplies. Late stages of heart failure are linked with low hepcidin levels, which are associated with worse outcomes. The exact mechanism of iron deficiency in heart failure patients is still not well elucidated, as different stages of heart failure are linked with variable hepcidin levels.

**DIAGNOSIS OF IRON DEFICIENCY AND ANEMIA**

Approximately 30% of heart failure patients present anemia, which is considered a predictor for mortality and morbidity in these patients, and iron deficiency plays an important role in the development of this condition. Female sex, advanced NYHA class, N-terminal pro-B natriuretic peptide (NT-proBNP), and C reactive protein (CRP) levels were identified as risk factors for iron deficiency. The total amount of iron in the body cannot be determined. The most accurate method for the evaluation of iron status is represented by bone marrow biopsy, but due to its invasiveness it is limitedly used in clinical practice. The most widely used biomarker for the evaluation of the iron status is the determination of ferritin level. However, clinical studies revealed that ferritin can underestimate low iron levels in heart failure patients, as bone marrow biopsies have shown cases of iron deficiency with normal serum ferritin levels. Chronic inflammatory status is also associated with higher ferritin levels; thus, some authors suggest that an index of soluble transferrin receptor (sTfR) and ferritin would define iron deficiency more accurately in heart failure patients. Current guidelines of the European Society of Cardiology (ESC) recommend (class I, level C) the routine determination of ferritin and transferrin saturation (TSAT) in all heart failure patients.

**TREATMENT OPTIONS FOR ANEMIA AND IRON DEFICIENCY**

Early studies that targeted the correction of anemia in heart failure patients and used erythropoiesis-stimulating agents such as erythropoietin and darbepoetin alfa showed promising results in terms of improvement of functional class, left ventricular ejection fraction, and hemoglobin levels. Later studies did not prove the reduction in mortality and hospital admissions and showed a significant increase in thromboembolic events, leading to the removal of these agents from the standard care of anemia in heart failure patients. Iron replacement with iron sucrose without the administration of erythropoietin therapy followed as an alternative for the correction of anemia and iron deficit in chronic heart failure patients. Intravenous iron administration is widely studied, as the first results have led to clinical (NYHA class, exercise capacity), quality of life, and laboratory (hemoglobin level, NT-pro-BNP) improvements. Further double-blind, multi-center studies investigated the long-term (52 weeks) effect and safety of intravenous iron (ferric carboxymaltose) administration. Positive results were recorded in terms of clinical improvement, correction of anemia, and improvement of 6-minute walking distance, with a decreased rate of hospitalization and worsening heart failure. Recent meta-analyses confirmed the safety and efficacy of intravenous iron with reduction of hospitalization rate, but with no significant effect on mortality. Current ongoing trials investigate the clinical outcomes and all-cause mortality with this treatment.

Intravenous iron administration is generally well tolerated. The large clinical trials that investigated intravenous
Iron administration in heart failure patients did not report any severe, life-threatening allergic reactions; however, observation of the patients is recommended after iron administration due to minor side effects such as minor allergic reactions, rashes, headache, or nausea. Paravenous administration may lead to long-term skin deposits at the injection site.24,28

Oral iron administration represents a therapeutic option for iron replacement in heart failure patients at relatively lower costs compared to intravenous administration. Abnormal absorption due to reduced blood flow of the gastrointestinal mucosa and frequent (more than half of the patients) side effects (e.g., diarrhea, nausea, vomiting, metal taste) significantly reduce the compliance to this administration form compared to the intravenous route.29,30 Few trials compared oral versus intravenous iron supplementation in chronic heart failure patients, but no significant increase of ferritin (as biomarker for iron storage) levels were recorded in patients with oral iron administration, and no changes were detected in peak oxygen consumption for these patients.30 Considering the above mentioned results, intravenous iron replacement therapy is preferred to oral administration in chronic heart failure patients.

Current ESC guidelines recommend (class IIa, level A) intravenous iron (ferric carboxymaltose) administration for symptomatic heart failure patients with reduced left ventricular ejection fraction if iron deficiency is identified, irrespective of anemia.7

FUTURE PERSPECTIVES

Ongoing clinical trials investigate the long-term efficiency of intravenous iron replacement therapy in chronic heart failure patients in terms of important end-points such as mortality, worsening heart failure, hospitalization, and quality of life.31,32 Research regarding more effective oral iron supplements, with better absorption and fewer side effects is also being carried out in the form of in vitro studies using nanoparticles and early clinical trials, with promising results.33–35 The identification of better laboratory biomarkers for detection of iron deficiency is also underway. Many trials suggested that serum ferritin levels may not describe the iron status of heart failure patients accurately due to a chronic inflammatory status in these patients.36,37

CONCLUSIONS

Iron deficiency and anemia are frequently associated in chronic heart failure patients, further impairing the functional capacity, quality of life, and mortality in this patient category. Intravenous iron replacement therapy, irrespective of anemia, alleviates the symptoms, reduces hospitalization, and improves the quality of life of these patients, therefore current guidelines advice for screening and correction of iron deficiency in chronic heart failure patients. The exact mechanism of action and the long-term safety and efficiency are still not well elucidated, thus further clinical trials are required.

CONFLICT OF INTEREST

Nothing to declare.

REFERENCES

contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;18:2129-2200.


32. Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: a Randomised, Open-label Multicentre Trial (IRONMAN) Available at: https://clinicaltrials.gov/ct2/show/NCT02642562


